CLINICAL_TRIALS
trial_result
· 2020-11-02
Clinical Trial Update: A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes [Phase 2]
Summary
Phase 2 trial of lenalidomide plus azacitidine in low-risk myelodysplastic syndromes (MDS) was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Rush University Medical Center | Conditions: MDS | Phase 2 | Status: TERMINATED | Results posted: 2020-11-02